Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1

Conditions

Melanoma 8Uveal Melanoma 3Carcinoma, Ovarian Epithelial 2Ovarian Neoplasms 1Myelodysplastic Syndromes 1Multiple Myeloma 1Mesothelioma, Malignant 1Lung Neoplasms 1Leukemia, Plasma Cell 1Leukemia 1Fallopian Tube Neoplasms 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Bortezomib 3filanesib 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Melphalan 2Lenalidomide 2Dexamethasone 2sargramostim 1montanide ISA 51 1merphos 1liposomal doxorubicin 1ixazomib 1itacitinib 1incomplete Freund's adjuvant 1fludarabine phosphate 1dexamethasone acetate 1dexamethasone 21-phosphate 1daratumumab 1carfilzomib 1auricularum 1Steroids 1Stem Cell Transplantation 1Sirolimus 1Proteasome Inhibitors 1Methotrexate 1Injections, Subcutaneous 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, Plasma Cell × incomplete Freund's adjuvant × Clear all
NCT02334865 2026-05-15

SVN53-67/M57-KLH Peptide Vaccine in Treating Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy

Roswell Park Cancer Institute

Phase 1 Active not recruiting
18 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡